ATTENSI
SAP SuccessFactors is the leading human capital management (HCM) solution, helping customers stay ahead of the competition to attract, develop and retain the best employees and ensuring a holistic employee journey throughout the employee lifecycle. Attensi delivers groundbreaking gamification and simulation-based training. Through this collaboration, the partners will offer an innovative learning experience using, among other approaches, gaming technology and competitive elements. The collaboration means that the two platforms work together to ensure a unified user experience and natural data flow, with the allocation and follow-up of learning as well as competence and development.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211208006137/en/
“We are currently in an era of change and rapid technological development where learning and competence development are becoming increasingly more important to businesses. It is incredibly rewarding to be able to embrace successful HR tech "scale-ups" such as Attensi, so that we can offer innovative technology like this as part of our open ecosystem to the benefit of our rapidly growing customer community."
– Jens Conradi, Sales Director, SAP SuccessFactors
The solutions that Attensi offers combines advanced 3D simulation with deep insight into human behavior and psychology. Employees encounter virtual scenarios that are individually adapted to the individual business and bring to life actual experiences from the organization's reality. As employees evolve, they get educational, personalized feedback, and scores on their results. In addition, Attensi allows you to engage employees with automated campaigns and communication. As a manager, you can easily follow your team in real time, provide feedback to your employees, and measure the impact of the learning.
"The collaboration with SAP SuccessFactors is of strategic importance to Attensi. We can now offer customers who use SuccessFactors a seamless learning experience where the best elements of SuccessFactors play together with Attensi's solutions and platform. This enables even better and faster competence development and behavioral training for all the millions of employees in the companies that use SuccessFactors."
– Trond Aas, CEO, Attensi
"This is a major milestone in the development of the Attensi Technology Platform! Having achieved all qualifications required by SAP to enter a partnership recognizes Attensi as a top player in the field. We are extremely excited to provide our users access to world-leading learning technology delivered seamlessly in SAP SuccessFactor's global platform."
– Anne Lise Waal, CTO & COO, Attensi
About Attensi
Attensi delivers next generation simulation-based learning technology based on game mechanics and behavioral psychology that impacts KPIs and drives change in large organizations. Attensi is headquartered in Oslo, Norway, with offices in UK, USA and Germany and has delivered over 500 simulation solutions in over 20 languages to a global user base.
About SAP SuccessFactors
SAP's solutions help more than 400,000 customers around the world work better together using business insights more efficiently. Originally known for ERP software, SAP has evolved to become the market leader in business applications and related services for data, analytics, and intelligent technologies.
SAP SuccessFactors is a cloud-based, holistic HR solution that supports the entire employee journey including recruitment, onboarding, talent development, payroll, and HR analytics. SAP SuccessFactors provides personalized user experiences that facilitate competence development and more engaged and productive employees. SAP SuccessFactors has 200 million users in over 7,000 businesses worldwide, of which over 40 Norway. The solution is located in 101 countries and supports 43 languages.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211208006137/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom